Conjugates of specific PBD dimers with an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence 5 according to any one of SEQ ID NOs. 2, 4, 6, 11,
Conjugates of specific PBD dimers with an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence 5 according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18.
대표청구항▼
1. A conjugate of formula ConjB: or ConjC wherein:the drug loading is from 1 to 8; Ab is an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence
1. A conjugate of formula ConjB: or ConjC wherein:the drug loading is from 1 to 8; Ab is an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18. 2. The conjugate according to claim 1 wherein the antibody comprises a VH domain paired with a VL domain, the VH and VL domains having sequences selected from the group consisting of: SEQ ID NO. 1 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;SEQ ID NO. 3 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;SEQ ID NO. 5 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;SEQ ID NO. 7 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;SEQ ID NO. 8 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;SEQ ID NO. 9 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18; or SEQ ID NO. 10 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18. 3. The conjugate according to claim 2 wherein the paired VH and VL domains have the sequences of: SEQ ID NO. 1 paired with SEQ ID NO. 2, SEQ ID NO. 3 paired with SEQ ID NO. 4, SEQ ID NO. 5 paired with SEQ ID NO. 6, SEQ ID NO. 7 paired with SEQ ID NO. 11, SEQ ID NO. 7 paired with SEQ ID NO. 12, SEQ ID NO. 7 paired with SEQ ID NO. 13, SEQ ID NO. 7 paired with SEQ ID NO. 14, SEQ ID NO. 7 paired with SEQ ID NO. 15, SEQ ID NO. 7 paired with SEQ ID NO. 16, SEQ ID NO. 7 paired with SEQ ID NO. 17, SEQ ID NO. 7 paired with SEQ ID NO. 18, SEQ ID NO. 8 paired with SEQ ID NO. 11, SEQ ID NO. 8 paired with SEQ ID NO. 12, SEQ ID NO. 8 paired with SEQ ID NO. 13, SEQ ID NO. 8 paired with SEQ ID NO. 14, SEQ ID NO. 8 paired with SEQ ID NO. 15, SEQ ID NO. 8 paired with SEQ ID NO. 16, SEQ ID NO. 8 paired with SEQ ID NO. 17, SEQ ID NO. 8 paired with SEQ ID NO. 18, SEQ ID NO. 9 paired with SEQ ID NO. 11, SEQ ID NO. 9 paired with SEQ ID NO. 12, SEQ ID NO. 9 paired with SEQ ID NO. 13, SEQ ID NO. 9 paired with SEQ ID NO. 14, SEQ ID NO. 9 paired with SEQ ID NO. 15, SEQ ID NO. 9 paired with SEQ ID NO. 16, SEQ ID NO. 9 paired with SEQ ID NO. 17, SEQ ID NO. 9 paired with SEQ ID NO. 18, SEQ ID NO. 10 paired with SEQ ID NO. 11, SEQ ID NO. 10 paired with SEQ ID NO. 12, SEQ ID NO. 10 paired with SEQ ID NO. 13, SEQ ID NO. 10 paired with SEQ ID NO. 14, SEQ ID NO. 10 paired with SEQ ID NO. 15, SEQ ID NO. 10 paired with SEQ ID NO. 16, SEQ ID NO. 10 paired with SEQ ID NO. 17, or SEQ ID NO. 10 paired with SEQ ID NO. 18. 4. The conjugate according to claim 1 wherein the antibody in an intact antibody. 5. The conjugate according to claim 1 wherein the antibody is humanised, deimmunised or resurfaced. 6. The conjugate according to claim 1, wherein the drug loading is 1, 2, 3, or 4. 7. A mixture of conjugates according to claim 1, wherein the average value of the drug loading is about 2 to about 5. 8. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient. 9. The pharmaceutical composition of claim 8 further comprising a therapeutically effective amount of a chemotherapeutic agent. 10. A method of treating prostate cancer comprising administering to a patient the pharmaceutical composition of claim 8. 11. The method of claim 10 wherein the patient is administered a therapeutically effective amount of a chemotherapeutic agent, in combination with the conjugate.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (74)
Howard, Philip Wilson; Gregson, Stephen John, 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines.
Howard, Philip Wilson; Thurston, David Edwin; Wells, Geoffrey, Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease.
Mottez Estelle,FRX ; Abastado Jean-Pierre,FRX ; Kourilsky Philippe,FRX, Altered major histocompatibility complex (MHC) determinant and method of using the determinant.
Mottez Estelle,FRX ; Abastado Jean-Pierre,FRX ; Kourilsky Philippe,FRX, Altered major histocompatibility complex (MHC) determinant and methods of using the determinant.
Chuntharapai Anan (460 Point San Bruno Blvd. South San Francisco CA 94080) Hbert Caroline (460 Point San Bruno Blvd. South San Francisco CA 94080) Kim Kyung J. (460 Point San Bruno Blvd. South San Fr, Antibodies to human IL-8 type B receptor.
McElroy ; deceased Marlene DeLuca (late of La Jolla CA by W. D. McElroy ; executor ) Helinski Donald Raymond (La Jolla CA) Wood Keith Vernon (San Diego CA) De Wet Jeffrey Roux (Menlo Park CA) Ow Davi, DNA sequences encoding coleoptera luciferase activity.
Fikes, John D.; Hermanson, Gary G.; Sette, Alessandro; Ishioka, Glenn Y.; Livingston, Brian; Chesnut, Robert W., Expression vectors for stimulating an immune response and methods of using the same.
Seon Ben K. (Williamsville NY), Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same fo.
Jegham Samir (Argenteuil FRX) Defosse Grard (Paris FRX) Purcell Thomas (Montfort L\Amaury FRX), Piperidine derivatives, their preparation and their application in therapeutics.
Ahmed Kamal IN; Chakravarthy Laxman Nallan IN; Ramesh Gujjar IN; Ramulu Poddutoori IN; Srinivas Olepu IN, Process for the preparation of antitumor agents.
Liu,Paul S; Vishnuvajjala,B. Rao; Snader,Kenneth M; Thurston,David E; Howard,Philip W; Hsiao,Luke Y; Turner,Gregory, Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto.
McElroy ; deceased Marlene D. (late of La Jolla CA) McElroy ; executor W. D. (San Diego CA) Helinski Donald R. (La Jolla CA) Wood Keith V. (San Diego CA) De Wet Jeffrey R. (Menlo Park CA) Ow David W., Recombinant expression of Coleoptera luciferase.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.